EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [1] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [2] DOCETAXEL RECHALLENGE VERSUS DOCETAXEL/BEVACIZUMAB IN CASTRATION-RESISTANT PROSTATE CANCER FOLLOWING FIRST LINE DOCETAXEL
    Heidenreich, A.
    Thueer, D.
    Pfister, D.
    Bernhard, B.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 283 - 284
  • [3] Docetaxel A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer
    McKeage, Kate
    DRUGS, 2012, 72 (11) : 1559 - 1577
  • [4] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [5] Docetaxel versus docetaxel plus bevacizumab in progressive castration-resistant prostate cancer following first-line docetaxel
    Heidenreich, A.
    Pfister, D. J.
    Thueer, D.
    Brehmer, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL
    Silva Miguel, L.
    Paquete, A. T.
    Guerreiro, R.
    Fiorentino, F.
    Costa, J.
    Borges, M.
    VALUE IN HEALTH, 2018, 21 : S71 - S71
  • [7] PREDICTORS OF RESPONSE TO DOCETAXEL RE-TREATMENT IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
    Sevcenco, S.
    Kramer, G.
    Klatte, T.
    Szendroi, A.
    Marberger, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 658
  • [8] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Akiyuki Yamamoto
    Masashi Kato
    Hirotaka Matsui
    Ryo Ishida
    Tohru Kimura
    Yasuhito Funahashi
    Naoto Sassa
    Yoshihisa Matsukawa
    Osamu Kamihira
    Ryohei Hattori
    Momokazu Gotoh
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2018, 23 : 584 - 590
  • [9] Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate
    Yamamoto, Akiyuki
    Kato, Masashi
    Matsui, Hirotaka
    Ishida, Ryo
    Kimura, Tohru
    Funahashi, Yasuhito
    Sassa, Naoto
    Matsukawa, Yoshihisa
    Kamihira, Osamu
    Hattori, Ryohei
    Gotoh, Momokazu
    Tsuzuki, Toyonori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 584 - 590
  • [10] Treatment patterns in men with castration-resistant prostate cancer receiving docetaxel
    Davis, Keith L.
    Gutierrez, Benjamin
    Zyczynski, Teresa Maria
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345